Tetraselmis chuii is a green marine alga used as an oral supplement for exercise recovery and cellular health. Moderate evidence from small, short, industry-funded studies shows low doses speed post-exercise strength recovery and higher doses improve sperm motility and live births in unexplained infertility. Endurance and body composition findings are conflicted. Low doses are well tolerated, while high doses caused minor blood shifts within normal limits. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Fasting Blood Glucose | 70–99 mg/dL (standard reference range) | Safety check: 200 mg/day raised fasting glucose (+8.0 mg/dL) in a 30-day trial; protocols reduce to 25 mg/day or stop if ≥100 mg/dL. |
| Serum Uric Acid | 3.5–7.2 mg/dL in men; 2.6–6.0 mg/dL in women (standard reference range) | Safety check: 200 mg/day increased serum uric acid in athletes; protocols discontinue use if uric acid rises above the upper reference limit. |
| Serum Creatinine | 0.7–1.3 mg/dL in men; 0.6–1.1 mg/dL in women (standard reference range) | Safety check: 200 mg/day elevated creatinine from 0.96 to 1.07 mg/dL; strenuous exercise is avoided for 24 hours before testing. |
| Platelet Count and Mean Platelet Volume (MPV) | Platelets: 150–450 × 10³/µL; MPV: 7.5–11.5 fL (standard reference range) | Safety check: two trials noted mild drops in platelet count or MPV; protocols stop if platelets drop below 150 × 10³/µL. |
| Serum Creatine Kinase (CK) | No established target; 24–48 hour post-exercise attenuation tracked relative to individual baseline | Expected to change: 25 mg/day lowered 24-hour post-damage log serum CK vs. placebo (sampled 24 hours post-exercise). |
| Countermovement Jump or Isometric RFD | No established target; maintenance or recovery to ≥95% of individual baseline tracked | Expected to change: 25 mg/day preserved 48-hour and 6-week rate of force development (RFD) on a force plate. |
Cadence: Baseline (comprehensive metabolic panel, serum uric acid, complete blood count, and countermovement jump or isometric pull force); follow-up at 2 and 6 weeks for 25 mg/day regimens, and at 4, 8, and 12 weeks (then every 3 to 6 months if cycled) for 200 to 250 mg/day regimens, with discontinuation if no measurable benefit is evident by 6 to 8 weeks.